Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Hangzhou Innogate Pharma Co. Ltd. is currently processing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being reviewed by 1 distinct examiner within 1 distinct art unit. The data reflects a concentrated effort in a highly specialized field, with the company's current patent activity focused on a concentrated point of examination.
The busiest examiner for the company is WEDDINGTON, KEVIN E, who is responsible for the 1 pending office action. Because the workload of WEDDINGTON, KEVIN E matches the total number of pending actions for the company, the immediate prosecution strategy is consolidated. This allows for a focused response to the specific requirements of the Biotechnology & Pharmaceuticals sector.
The use of 1 distinct art unit for the 1 pending office action indicates that the company's current filings are not spread across different technical divisions at the USPTO. This concentration simplifies the management of the portfolio, as all current activity is confined to a single examiner. Practitioners can direct all resources toward the specific examination process in the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEDDINGTON, KEVIN E | 1 | 75.2% | +9.8% |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264949 | COMPOUND SERVING AS NLRP3 INHIBITOR | WEDDINGTON, KEVIN E | 1629 | §112Other | Non-Final OA | — | Pending | Mar 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial